FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050367032> ?p ?o ?g. }

• W2050367032 abstract "Background Effective anti-TNF treatment in large doses may affect sperm count and reduce fertility.1,2,3 More controlled clinical studies to investigate effects of anti-TNF agents on semen quality are required. Objectives To examine the effect of a single dose of certolizumab pegol (CZP) on the semen quality of healthy subjects, to identify the intra- and inter-subject variability in semen quality variables at baseline, and to investigate the safety and tolerability of CZP treatment. Methods 20 healthy males were included in this phase 1, single-centre, double-blind, placebo (PBO)-controlled study (NCT01091220). Subjects were randomized in a 3:1 ratio to receive CZP 400mg (2x200mg subcutaneous injections) or PBO. A screening period (up to 3 weeks) was followed by a 14 week follow up period after the day of dosing. Primary variables for assessment of semen included total motility and morphology (% of normal ovoid forms by Tygerberg criteria4). Treatment effects were assessed using a linear repeated measures model. A mixed effect model (visit - fixed effect; subject - random effect) was applied to the screening data to assess intra- and inter-subject variability. Safety of CZP was evaluated by the number of adverse events (AEs) and routine biochemistry and haemotology laboratory analyses. Results Highest intra-subject variability was found in non progressive motility, spermatozoa count and concentration (66.2%, 43.9% and 36.2%, respectively). Highest inter-subject variability was detected in spermatozoa count, concentration, semen volume and morphology (61.7%, 52.2%, 45.4% and 36.3%, respectively). CZP treatment was found to have no effect on the semen quality variables assessed vs PBO (Table). The changes in semen quality variables during the treatment period were generally within the range of intra- and inter-subject variability seen during screening. The reporting of AEs was broadly similar between the two arms. No AEs were regarded as serious or led to discontinuation from the study. Conclusions Considerable intra- and inter-subject semen quality variability exists in healthy male subjects. A single 400mg CZP dose was well tolerated and did not produce any treatment effects on semen quality in healthy males compared to PBO. References Pentikainen et al. J Clin Endocrinol Metab. 2001;86(9):4480-82. Suominen et al.Eur J Endocrinol. 2004;151(5):629-40 2004. Mahadevan et al. Inflamm Bowel Dis. 2005;11(4):395-9. World Health Organization. WHO Laboratory Manual for the Examination and Processing of Human Semen. 5th ed. Geneva: World Health Organization Press; 2010. Disclosure of Interest S. Perrier d’Hauterive Grant/Research support from: UCB Pharma, S. Kesseler Grant/Research support from: UCB Pharma, P. Ruggeri Grant/Research support from: UCB Pharma, M. Timmermans Grant/Research support from: UCB Pharma, O. Gaspard Grant/Research support from: UCB Pharma, T. Kumke Employee of: UCB Pharma, G. Parker Employee of: UCB Pharma" @default.
• W2050367032 created "2016-06-24" @default.
• W2050367032 creator A5020853691 @default.
• W2050367032 creator A5027388423 @default.
• W2050367032 creator A5027472852 @default.
• W2050367032 creator A5042655551 @default.
• W2050367032 creator A5062755282 @default.
• W2050367032 creator A5071222208 @default.
• W2050367032 creator A5085107935 @default.
• W2050367032 date "2013-06-01" @default.
• W2050367032 modified "2023-09-27" @default.
• W2050367032 title "FRI0160 Certolizumab PEGOL did not result in a decrease in semen quality in healthy volunteers: Results from a phase 1 study:" @default.
• W2050367032 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2617" @default.
• W2050367032 hasPublicationYear "2013" @default.
• W2050367032 type Work @default.
• W2050367032 sameAs 2050367032 @default.
• W2050367032 citedByCount "0" @default.
• W2050367032 crossrefType "journal-article" @default.
• W2050367032 hasAuthorship W2050367032A5020853691 @default.
• W2050367032 hasAuthorship W2050367032A5027388423 @default.
• W2050367032 hasAuthorship W2050367032A5027472852 @default.
• W2050367032 hasAuthorship W2050367032A5042655551 @default.
• W2050367032 hasAuthorship W2050367032A5062755282 @default.
• W2050367032 hasAuthorship W2050367032A5071222208 @default.
• W2050367032 hasAuthorship W2050367032A5085107935 @default.
• W2050367032 hasConcept C126322002 @default.
• W2050367032 hasConcept C142724271 @default.
• W2050367032 hasConcept C16685009 @default.
• W2050367032 hasConcept C197934379 @default.
• W2050367032 hasConcept C204787440 @default.
• W2050367032 hasConcept C27081682 @default.
• W2050367032 hasConcept C2776215756 @default.
• W2050367032 hasConcept C2777226972 @default.
• W2050367032 hasConcept C2777288759 @default.
• W2050367032 hasConcept C2777575956 @default.
• W2050367032 hasConcept C2777589648 @default.
• W2050367032 hasConcept C2777688143 @default.
• W2050367032 hasConcept C2778080409 @default.
• W2050367032 hasConcept C2778093475 @default.
• W2050367032 hasConcept C2778375690 @default.
• W2050367032 hasConcept C2779234561 @default.
• W2050367032 hasConcept C2781087480 @default.
• W2050367032 hasConcept C54355233 @default.
• W2050367032 hasConcept C71924100 @default.
• W2050367032 hasConcept C86803240 @default.
• W2050367032 hasConceptScore W2050367032C126322002 @default.
• W2050367032 hasConceptScore W2050367032C142724271 @default.
• W2050367032 hasConceptScore W2050367032C16685009 @default.
• W2050367032 hasConceptScore W2050367032C197934379 @default.
• W2050367032 hasConceptScore W2050367032C204787440 @default.
• W2050367032 hasConceptScore W2050367032C27081682 @default.
• W2050367032 hasConceptScore W2050367032C2776215756 @default.
• W2050367032 hasConceptScore W2050367032C2777226972 @default.
• W2050367032 hasConceptScore W2050367032C2777288759 @default.
• W2050367032 hasConceptScore W2050367032C2777575956 @default.
• W2050367032 hasConceptScore W2050367032C2777589648 @default.
• W2050367032 hasConceptScore W2050367032C2777688143 @default.
• W2050367032 hasConceptScore W2050367032C2778080409 @default.
• W2050367032 hasConceptScore W2050367032C2778093475 @default.
• W2050367032 hasConceptScore W2050367032C2778375690 @default.
• W2050367032 hasConceptScore W2050367032C2779234561 @default.
• W2050367032 hasConceptScore W2050367032C2781087480 @default.
• W2050367032 hasConceptScore W2050367032C54355233 @default.
• W2050367032 hasConceptScore W2050367032C71924100 @default.
• W2050367032 hasConceptScore W2050367032C86803240 @default.
• W2050367032 hasLocation W20503670321 @default.
• W2050367032 hasOpenAccess W2050367032 @default.
• W2050367032 hasPrimaryLocation W20503670321 @default.
• W2050367032 hasRelatedWork W1533704259 @default.
• W2050367032 hasRelatedWork W1565997261 @default.
• W2050367032 hasRelatedWork W2005028628 @default.
• W2050367032 hasRelatedWork W2015707622 @default.
• W2050367032 hasRelatedWork W2090372920 @default.
• W2050367032 hasRelatedWork W2316010001 @default.
• W2050367032 hasRelatedWork W2335934270 @default.
• W2050367032 hasRelatedWork W2341533085 @default.
• W2050367032 hasRelatedWork W2411380196 @default.
• W2050367032 hasRelatedWork W2809511961 @default.
• W2050367032 hasRelatedWork W2977716037 @default.
• W2050367032 hasRelatedWork W3020717248 @default.
• W2050367032 hasRelatedWork W3023230046 @default.
• W2050367032 hasRelatedWork W3027071520 @default.
• W2050367032 hasRelatedWork W3034459315 @default.
• W2050367032 hasRelatedWork W3087386396 @default.
• W2050367032 hasRelatedWork W3131966181 @default.
• W2050367032 hasRelatedWork W3158494045 @default.
• W2050367032 hasRelatedWork W3163980494 @default.
• W2050367032 hasRelatedWork W3206416834 @default.
• W2050367032 isParatext "false" @default.
• W2050367032 isRetracted "false" @default.
• W2050367032 magId "2050367032" @default.
• W2050367032 workType "article" @default.